摘要
目的:探讨晚期卵巢透明细胞癌术前血清CA125水平与瘤体减灭术满意与否的相关性。方法:回顾分析21例晚期卵巢透明细胞癌患者的临床和病理特点,并采用四格表确切概率计算法分析术前血清CA125水平与瘤体减灭术满意度的关系。结果:术前血清CA125>35IU/ml者16例(76.1%)。根据术前血清CA125水平是否≥500IU/ml将21例患者分为两组:CA125≥500IU/ml者9例(42.86%),其中瘤体减灭术满意1例,不满意8例;CA125<500IU/ml者12例(57.14%),其中瘤体减灭术满意6例,不满意6例。CA125≥500IU/ml组的瘤体减灭术满意率明显高于CA125<500IU/ml组,但无统计学差异(P=0.078)。结论:利用术前CA125血清学水平预测瘤体减灭术的满意度有一定的局限性。
Objective:To investigate the association between the debulking surgery and the preoperative serum CA125 levels in advanced ovarian clear cell carcinoma(FIGO Ⅲor Ⅳstage).Methods:The clinical and pathologic features of the 21 cases of advanced ovarian clear cell carcinoma were retrospectively analysed.The Fisher exact test was applied to identify the association between the preoperative serum CA125 levels and the debulking surgery.Results:The preoperative serum CA125 levels were >35 U/ml in 16 cases(76.1%).According to the preoperative serum CA125 levels,the 21 cases were divided into two groups:≥500 U/ml and<500 U/ml.There were 9 cases(42.86%)with CA125 ≥500 U/ml,and only one of this 9 cases had received optimal debulking surgery.Among the cases with CA125<500 U/ml,6 cases had received optimal debulking surgery.Although the optimal rates were different between the two groups,there were no statistical significance(P=0.078).Conclusion:The clinical applicability of preoperative serum CA125 levels to predict the optimal debulking surgery is limited.
出处
《现代妇产科进展》
CSCD
北大核心
2007年第3期217-219,共3页
Progress in Obstetrics and Gynecology
